Retrospective cohort identifies risk factors and predicts postherpetic neuralgia risk in patients with herpes zoster.
This retrospective cohort study included 846 patients with herpes zoster from the Affiliated Hospital of Putian University and Zhangzhou Affiliated Hospital of Fujian Medical University. The population was divided into 627 training and 219 validation subsets. The primary objective was the prediction of postherpetic neuralgia risk following herpes zoster onset. Key risk factors identified included age, timing of antiviral therapy, acute pain severity, prodromal phase pain, and diabetes.
The study utilized an XGBoost model to assess prediction performance. PHN incidence was 19.0% in the training set and 22.8% in the validation set. Specifically, 119 of 627 training patients and 50 of 219 validation patients developed the condition. Model performance metrics included accuracy, sensitivity, F1 score, calibration, and clinical utility.
The XGBoost model AUC was 0.826 in the training cohort and 0.840 in the validation cohort. The 95%CI was 0.786–0.866 for training and 0.784–0.896 for validation. Follow-up duration was not reported. Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported.
Limitations include the retrospective observational design and model validation limited to two specific cohorts. The causality note indicates an observational association where risk factors were identified via feature selection, but causation was not established. Important practice relevance currently suggests this tool can assist clinicians in early risk stratification and guide personalized management for patients with HZ.